Partial
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Several key label elements are misstated or not supported (notably the treatment indication and multiple safety risk claims). One claim found in the content provided also directly contradicts the label language on calcium/vitamin D.
Category Scores
Accurate Statements
Elagolix is a GnRH receptor antagonist.
Supported (11 DESCRIPTION; GnRH receptor antagonist) and 12.1 Mechanism of Action.
Administration of ORILISSA suppresses LH and FSH and decreases blood concentrations of ovarian sex hormones, estradiol and progesterone.
Supported (12.1 Mechanism of Action).
ORILISSA causes a dose-dependent decrease in bone mineral density (BMD).
Supported (5.1 Bone Loss).
BMD loss is greater with increasing duration and may not be completely reversible after stopping treatment.
Supported (5.1 Bone Loss).
ORILISSA is contraindicated in women with known osteoporosis.
Supported (5.1 Bone Loss; contraindicated in women with known osteoporosis).
Common side effects could include hot flashes.
Not supported by the provided label excerpts (no adverse reaction list provided in the prompt beyond serious adverse reactions and headings).
Unsupported Statements
Orilissa is a brand-name medication used to treat heavy menstrual bleeding associated with uterine fibroids.
The provided label text indicates ORILISSA is indicated for moderate to severe pain associated with endometriosis (1 INDICATIONS AND USAGE). Heavy menstrual bleeding due to uterine fibroids is not supported by the supplied label excerpts.
There is no generic version of Orilissa currently available.
Not addressed in the supplied prescribing information excerpts.
The active ingredient in Orilissa is elagolix.
Not explicitly stated in the provided excerpts as 'active ingredient' wording, though the label describes ORILISSA (elagolix) and contains elagolix sodium; direct wording 'active ingredient is elagolix' is not explicitly quoted in the provided text.
Reducing estrogen and progesterone can decrease uterine fibroid growth.
Not supported in the supplied label excerpts; label mechanism is described for ovarian sex hormones but fibroid growth benefit is not stated.
Reducing estrogen and progesterone can reduce menstrual bleeding.
Not supported by the supplied label excerpts as stated (although change in menstrual bleeding pattern is mentioned as a serious adverse reaction concept, not as a therapeutic effect).
Orilissa carries an increased risk of blood clots.
No blood clot risk is mentioned in the supplied label excerpts.
Orilissa carries an increased risk of stroke.
No stroke risk is mentioned in the supplied label excerpts.
Orilissa carries an increased risk of heart attack.
No heart attack risk is mentioned in the supplied label excerpts.
Common side effects of Orilissa can include nausea.
The provided excerpts do not list nausea as a common side effect.
Common side effects of Orilissa can include stomach pain.
The provided excerpts do not list stomach pain as a common side effect.
Common side effects of Orilissa can include irregular bleeding.
The label excerpts mention 'Change in menstrual bleeding pattern...' as a serious adverse reaction discussed elsewhere, but the claim is framed as 'common side effects.' The commonality is not supported in the provided text.
Contradictions
Low
AI Statement
Effect of calcium and vitamin D supplementation was studied in all patients and is proven beneficial.
Label Reference
5.1 Bone Loss: 'Although the effect of supplementation with calcium and vitamin D was not studied, such supplementation may be beneficial for all patients.'
Important Omissions
The correct FDA-approved indication (moderate to severe pain associated with endometriosis) is omitted/replaced with an unsupported fibroids/heavy bleeding indication, which is material for accurate label alignment.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Multiple safety claims (blood clots, stroke, heart attack) are not supported by the supplied label excerpts, and the indication is misstated, which together could mislead clinical decision-making. One claim directly contradicts the label regarding calcium/vitamin D supplementation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Not Aligned
Primary Issue
Incorrect indication and multiple unsupported safety/side-effect claims not present in the provided prescribing information.
Suggested Improvement
Align indication to: 'management of moderate to severe pain associated with endometriosis' (1 INDICATIONS AND USAGE), and restrict safety/side-effect statements to items explicitly supported in the provided label excerpts (e.g., bone loss and contraindication in known osteoporosis; discuss only labeled adverse reactions with correct categorization). Remove or rephrase unsupported risks (blood clots/stroke/heart attack) and avoid stating calcium/vitamin D were studied as beneficial when the label says it was not studied.